Vertex Pharmaceuticals (VRTX) Retained Earnings (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Retained Earnings of $14.6 billion for Q1 2026, up 21326.43% year-over-year from N/an in Q1 2025, and up 7.61% quarter-over-quarter from $13.6 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Retained Earnings (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $14.6 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 21326.43% year-over-year to $14.6 billion; the TTM figure through Mar 2026 stood at $14.6 billion (up 21326.43% YoY), while the FY2025 annual figure was $13.6 billion, up 10510.33% from the prior year.
- Retained Earnings for Q1 2026 stood at $14.6 billion, up from $13.6 billion in the prior quarter.
- The five-year high for Retained Earnings was $14.6 billion in Q1 2026, with the low at -$64.5 million in Q3 2025.
- The 5-year median for Retained Earnings is $68.1 million (2025), against an average of $3.5 billion.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 1887.5% in 2023, then jumped 289893.33% in 2024.
- Vertex Pharmaceuticals' Retained Earnings stood at $800000.0 in 2022, then plunged by 1887.5% to -$14.3 million in 2023, then soared by 993.71% to $127.8 million in 2024, then soared by 10510.33% to $13.6 billion in 2025, then rose by 7.61% to $14.6 billion in 2026.
- Business Quant data shows VRTX's Retained Earnings at $14.6 billion in Q1 2026, $13.6 billion in Q4 2025, and -$64.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.69 Bn |
| Mar 31, 2026 | 14.59 Bn |
| Dec 31, 2025 | 13.56 Bn |
| Sep 30, 2025 | -64.50 Mn |
| Jun 30, 2025 | 11.29 Bn |
| Mar 31, 2025 | 68.10 Mn |
| Dec 31, 2024 | 127.80 Mn |
| Sep 30, 2024 | 8.69 Bn |
| Jun 30, 2024 | 7.65 Bn |
| Mar 31, 2024 | 17.30 Mn |
| Dec 31, 2023 | -14.30 Mn |
| Sep 30, 2023 | -3.00 Mn |
| Jun 30, 2023 | -39.80 Mn |
| Mar 31, 2023 | -13.10 Mn |
| Dec 31, 2022 | 800,000.00 |
| Sep 30, 2022 | 97.60 Mn |
| Jun 30, 2022 | 57.50 Mn |
| Mar 31, 2022 | 3.96 Bn |
| Dec 31, 2021 | 3.20 Bn |
| Sep 30, 2021 | 11.54 Mn |